TY - JOUR
T1 - Human papillomavirus genotype attribution in invasive cervical cancer
T2 - a retrospective cross-sectional worldwide study
AU - de Sanjose, Silvia
AU - Quint, Wim G.V.
AU - Alemany, Laia
AU - Geraets, Daan T.
AU - Klaustermeier, Jo Ellen
AU - Lloveras, Belen
AU - Tous, Sara
AU - Felix, Ana
AU - Bravo, Luis Eduardo
AU - Shin, Hai Rim
AU - Vallejos, Carlos S.
AU - de Ruiz, Patricia Alonso
AU - Lima, Marcus Aurelho
AU - Guimera, Nuria
AU - Clavero, Omar
AU - Alejo, Maria
AU - Llombart-Bosch, Antonio
AU - Cheng-Yang, Chou
AU - Tatti, Silvio Alejandro
AU - Kasamatsu, Elena
AU - Iljazovic, Ermina
AU - Odida, Michael
AU - Prado, Rodrigo
AU - Seoud, Muhieddine
AU - Grce, Magdalena
AU - Usubutun, Alp
AU - Jain, Asha
AU - Suarez, Gustavo Adolfo Hernandez
AU - Lombardi, Luis Estuardo
AU - Banjo, Aekunbiola
AU - Menéndez, Clara
AU - Domingo, Efrén Javier
AU - Velasco, Julio
AU - Nessa, Ashrafun
AU - Chichareon, Saibua C.Bunnag
AU - Qiao, You Lin
AU - Lerma, Enrique
AU - Garland, Suzanne M.
AU - Sasagawa, Toshiyuki
AU - Ferrera, Annabelle
AU - Hammouda, Doudja
AU - Mariani, Luciano
AU - Pelayo, Adela
AU - Steiner, Ivo
AU - Oliva, Esther
AU - Meijer, Chris J.L.M.
AU - Al-Jassar, Waleed Fahad
AU - Cruz, Eugenia
AU - Wright, Thomas C.
AU - Puras, Ana
AU - Llave, Cecilia Ladines
AU - Tzardi, Maria
AU - Agorastos, Theodoros
AU - Garcia-Barriola, Victoria
AU - Clavel, Christine
AU - Ordi, Jaume
AU - Andújar, Miguel
AU - Castellsagué, Xavier
AU - Sánchez, Gloria I.
AU - Nowakowski, Andrzej Marcin
AU - Bornstein, Jacob
AU - Muñoz, Nubia
AU - Bosch, F. Xavier
PY - 2010/11
Y1 - 2010/11
N2 - Background: Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer. Methods: Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and information about the year of diagnosis. HPV detection was done by use of PCR with SPF-10 broad-spectrum primers followed by DNA enzyme immunoassay and genotyping with a reverse hybridisation line probe assay. Sequence analysis was done to characterise HPV-positive samples with unknown HPV types. Data analyses included algorithms of multiple infections to estimate type-specific relative contributions. Findings: 22 661 paraffin-embedded samples were obtained from 14 249 women. 10 575 cases of invasive cervical cancer were included in the study, and 8977 (85%) of these were positive for HPV DNA. The most common HPV types were 16, 18, 31, 33, 35, 45, 52, and 58 with a combined worldwide relative contribution of 8196 of 8977 (91%, 95% CI 90-92). HPV types 16 and 18 were detected in 6357 of 8977 of cases (71%, 70-72) of invasive cervical cancer. HPV types 16, 18, and 45 were detected in 443 of 470 cases (94%, 92-96) of cervical adenocarcinomas. Unknown HPV types that were identified with sequence analysis were 26, 30, 61, 67, 69, 82, and 91 in 103 (1%) of 8977 cases of invasive cervical cancer. Women with invasive cervical cancers related to HPV types 16, 18, or 45 presented at a younger mean age than did those with other HPV types (50·0 years [49·6-50·4], 48·2 years [47·3-49·2], 46·8 years [46·6-48·1], and 55·5 years [54·9-56·1], respectively). Interpretation: To our knowledge, this study is the largest assessment of HPV genotypes to date. HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines. Our results also suggest that type-specific high-risk HPV-DNA-based screening tests and protocols should focus on HPV types 16, 18, and 45. Funding: Spanish grants from Instituto de Salud Carlos III, Agència de Gestió d'Ajuts Universitaris i de Recerca, Marató de TV3 Foundation, and unrestricted grants from GlaxoSmithKline Biologicals, Sanofi Pasteur MSD, and Merck.
AB - Background: Knowledge about the distribution of human papillomavirus (HPV) genotypes in invasive cervical cancer is crucial to guide the introduction of prophylactic vaccines. We aimed to provide novel and comprehensive data about the worldwide genotype distribution in patients with invasive cervical cancer. Methods: Paraffin-embedded samples of histologically confirmed cases of invasive cervical cancer were collected from 38 countries in Europe, North America, central South America, Africa, Asia, and Oceania. Inclusion criteria were a pathological confirmation of a primary invasive cervical cancer of epithelial origin in the tissue sample selected for analysis of HPV DNA, and information about the year of diagnosis. HPV detection was done by use of PCR with SPF-10 broad-spectrum primers followed by DNA enzyme immunoassay and genotyping with a reverse hybridisation line probe assay. Sequence analysis was done to characterise HPV-positive samples with unknown HPV types. Data analyses included algorithms of multiple infections to estimate type-specific relative contributions. Findings: 22 661 paraffin-embedded samples were obtained from 14 249 women. 10 575 cases of invasive cervical cancer were included in the study, and 8977 (85%) of these were positive for HPV DNA. The most common HPV types were 16, 18, 31, 33, 35, 45, 52, and 58 with a combined worldwide relative contribution of 8196 of 8977 (91%, 95% CI 90-92). HPV types 16 and 18 were detected in 6357 of 8977 of cases (71%, 70-72) of invasive cervical cancer. HPV types 16, 18, and 45 were detected in 443 of 470 cases (94%, 92-96) of cervical adenocarcinomas. Unknown HPV types that were identified with sequence analysis were 26, 30, 61, 67, 69, 82, and 91 in 103 (1%) of 8977 cases of invasive cervical cancer. Women with invasive cervical cancers related to HPV types 16, 18, or 45 presented at a younger mean age than did those with other HPV types (50·0 years [49·6-50·4], 48·2 years [47·3-49·2], 46·8 years [46·6-48·1], and 55·5 years [54·9-56·1], respectively). Interpretation: To our knowledge, this study is the largest assessment of HPV genotypes to date. HPV types 16, 18, 31, 33, 35, 45, 52, and 58 should be given priority when the cross-protective effects of current vaccines are assessed, and for formulation of recommendations for the use of second-generation polyvalent HPV vaccines. Our results also suggest that type-specific high-risk HPV-DNA-based screening tests and protocols should focus on HPV types 16, 18, and 45. Funding: Spanish grants from Instituto de Salud Carlos III, Agència de Gestió d'Ajuts Universitaris i de Recerca, Marató de TV3 Foundation, and unrestricted grants from GlaxoSmithKline Biologicals, Sanofi Pasteur MSD, and Merck.
UR - http://www.scopus.com/inward/record.url?scp=78049528352&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(10)70230-8
DO - 10.1016/S1470-2045(10)70230-8
M3 - Article
C2 - 20952254
AN - SCOPUS:78049528352
SN - 1470-2045
VL - 11
SP - 1048
EP - 1056
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 11
ER -